I recently completed Science Business: The Promise, the Reality, and the Future of Biotech. Time spent reading was a rewarding allocation sans for Part I where author Gary Pisano, Professor of Business Administration at Harvard Business School, focuses upon a survey of the technologies, tools and theories that the biotechnology industry is built upon. Don’t [...]

• 198http://clsdf.com/2007/08/science-biz-what-happened-to-biotech/Science+Biz%3A+What+Happened+to+Biotech%3F2007-08-07+01%3A33%3A00admin

Some great events are coming up in August, be certain to mark you calendars, and please stop me to say hi. 14 August 2007 BioBoulder @ Rembrant Yard (Sponsors: CBSA, Amgen, Hogan & Hartson) 16 August 2007 Biotech Accounting Hot Topics @ E&Y Denver (Sponsors: CBSA, Ernst & Young) 22 August 2007 Medical Device Symposium [...]

• 197http://clsdf.com/2007/08/mark-your-calendars/Mark+Your+Calendars%212007-08-01+17%3A21%3A00admin

The following is a message from Dr. J. William Freytag, President and CEO of Aspreva Pharma (NASDAQ: ASPV) and former helmsman of Myogen who lead the $2.5 billion exit to Gilead (NASDAQ: GILD). If one subscribes to the notion of “betting on management” such an investor may be unquestionably moved to pick up some shares [...]

• 196http://clsdf.com/2007/08/following-along-with-dr-bill-freytag%e2%80%a6/Following+Along+With+Dr.+Bill+Freytag%E2%80%A62007-08-01+16%3A12%3A00admin